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ABSTRACT Candida pseudohaemulonii is phylogenetically close to the C. haemulonii
complex and exhibits resistance to amphotericin B and azole agents. We report
here the draft genome sequence of C. pseudohaemulonii UZ153_17 isolated from
the blood culture of a neutropenic patient. The draft genome is 3,532,003,666 bp in
length, with 579,838 reads, 130 contigs, and a GC content of 47.15%.
Candida pseudohaemulonii was first isolated in 2006 from the blood of a patient inThailand (1). It is phylogenetically similar to C. haemulonii, which is also resistant to
amphotericin B. C. pseudohaemulonii cannot be well differentiated by current commer-
cial identification methods from its other related species, C. haemulonii, C. haemulonii
var. vulnera, C. duobushaemulonii, and C. auris. Thus, a molecular barcode was proposed
for fungal identification, namely, the internal transcribed spacer (ITS) region, the D1/D2
domain of the large subunit (LSU) region in the rRNA gene, and the matrix-assisted laser
desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) (2). In this
article, we report the draft genome sequence of C. pseudohaemulonii UZ153_17 iso-
lated from the blood culture of a neutropenic patient with short bowel syndrome.
DNA was extracted using the cetyltrimethylammonium bromide (CTAB) method (3),
and a DNA library was prepared following the Illumina protocol using a TruSeq DNA LT
sample prep kit (Illumina, San Diego, CA, USA). The genomic DNA was sequenced to a
451-fold depth of coverage using the Illumina HiSeq 2500 platform. From our analysis,
the estimated genome size of C. pseudohaemulonii UZ153_17 is 14.74 Mb. The resulting
draft genome’s total size is 3,532,003,666 bp, with an overall GC content of 47.15%.
The genome was assembled into 130 contigs using the SOAPdenovo version 2.04
assembler (4). All of the generated contigs were formed into 90 scaffolds, of which 47
are more than 1,000 bp in length, with a scaffold N50 size of 799,808 bp. The total size
of all the scaffolds is 12,700,538 bp. Subsequent gene prediction analysis using MAKER2 (5)
yielded a total of 5,540 predicted protein-coding genes with an average length of
1,492 bp. Genome annotation on the predicted genes was carried out by BLAST
similarity searches against Swiss-Prot, a protein sequence database, with a total of
60.99% genes successfully annotated.
The genome is found to contain fluconazole and multidrug resistance genes. This
finding is parallel with other studies that have shown that the isolate was resistant to
amphotericin B and fluconazole (1, 2). The draft genome sequence of C. pseudohaemu-
lonii will contribute to further investigations into the molecular mechanisms that lead
to antifungal drug resistance.
Accession number(s). The nucleotide sequence of the C. pseudohaemulonii
UZ153_17 genome has been deposited in DDBJ/EMBL/GenBank under accession no.
PEJZ00000000.
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